End-of-day quote
Other OTC
- USD
-
Sales 2022
0.57
Sales 2023
0.61
Capitalization
5.54M
Net income 2022
-12M
Net income 2023
-30M
EV / Sales 2022
44,915,754
x
Net Debt
2022
3.98M
Net Debt
2023
18.76M
EV / Sales 2023
40,045,900
x P/E ratio 2022
-1.59
x
P/E ratio 2023
-0.18
x
Employees
-
Yield 2022 *
-
Yield 2023
-
Free-Float
17.39%
Theralink Technologies, Inc. cancelled the acquisition of IMAC Holdings, Inc. in a reverse merger transaction.
May. 05
CI
Theralink Technologies, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
Feb. 20
CI
Theralink Technologies, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
Jan. 05
CI
Theralink Technologies, Inc. Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute?s Molecular Tumor Board
Nov. 03
CI
Theralink Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
23-08-21
CI
IMAC Holdings, Inc. announced that it has received $4.3 million in funding from Theralink Technologies, Inc. and other investors
23-07-25
CI
Theralink Technologies, Inc. Announces Chief Executive Officer Changes
23-06-27
CI
Theralink Technologies, Inc. Appoints Mick Ruxin as Chief Medical Officer
23-06-27
CI
Theralink Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
23-05-15
CI
Theralink Technologies, Inc. entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. for $0.9 million in a reverse merger transaction.
23-05-14
CI
Theralink Technologies, Inc. Announces Termination of Thomas Chilcott as Treasurer and Secretary
23-05-11
CI
Theralink Technologies, Inc. Announces CFO Changes
23-05-11
CI
Theralink Technologies, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022
23-02-21
CI
Theralink Technologies, Inc. announced that it has received $4 million in funding from Cavalry Fund I Management, LLC
23-01-26
CI
Theralink Technologies Appoints Michael Vallone as Senior Director of Commercialization
23-01-09
CI
More news
Managers
Title Age Since
Chief Executive Officer
49
22-12-04
Director of Finance/CFO
43
08-12-31
Chief Tech/Sci/R&D Officer
78
17-12-31
Members of the board
Title Age Since
Chairman
66
20-06-17
Chief Tech/Sci/R&D Officer
78
17-12-31
Director of Finance/CFO
43
08-12-31
More insiders
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.
More about the company
1st Jan change
Capi.
+7.52% 113B +11.38% 106B +0.58% 22.27B -12.64% 22.22B -3.90% 19.43B -37.85% 17.87B -8.58% 17.24B +7.77% 14.29B +37.41% 12.52B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**